

- 1. Membrane stabilizer and excitability in isolated rat soleus muscle**  
Albeson C, Clarke D, Cookson J, Cunningham S, Kohn PG, Kumari P, Miller C, Woodham S. J, of Physiol. 1982;334:36-37P
- 2. The measurement of broadband ultrasonic attenuation in cancellous bone**  
Langton CM, Miller CG, Porter RW, Palmer SB. British J. of Radiol. 1985;58:691
- 3. Back pain and trunk list**  
Porter RW, Miller CG. Spine 1986; 11(6):596-600
- 4. Ultrasound attenuation in the os calcis**  
Porter RW, Miller CG, Langton CM, Rogers L, Palmer SB, In Back Pain: New methods for clinical investigation and assessment. Edited by Hukins DWL, Mulholland RC. 1986 Manchester University Press.
- 5. The relationship between broadband ultrasonic attenuation in the os calcis and post-menopausal fractures**  
Porter RW, Miller CG, Langton CM. Bone 1987; 8:45-55.
- 6. The prediction of fracture of the proximal femur by broadband ultrasonic attenuation**  
Miller CG, Porter RW. In The International Symposium on Osteoporosis, Denmark 1987. Edited by Christiansen C, Johansen JS, Riis BJ.
- 7. Broadband ultrasonic attenuation as a predictive index for hip fracture in the elderly**  
Miller CG, Porter RW. In Ultrasonic Assessment of Bone. Edited by Palmer SB, Langton CM. IOP Publishing Short meeting series No. 6. 1987.
- 8. Specificity and sensitivity of ultrasound attenuation in bone**  
Murray SA, Miller CG, Kanis JA, in Ultrasonic studies of bone. Edited by Palmer SB, Langton CM. IOP Publishing Short meeting series No. 6, 1987.
- 9. The prediction of fracture of the proximal femur by broadband ultrasonic attenuation**  
Miller CG, Porter RW. Clin. Phys. Physiol. Meas. 1988; 9(2):180.
- 10. The prediction of hip fracture in the elderly by the measurement of broadband ultrasonic attenuation through the os calcis**  
Miller CG, Porter RW, Smith PC, Grainger D, Palmer SB. In Osteoporosis and Bone Mineral Measurement. Edited by Ring EFG, Evans WD, Dixon AS Institute of Physical Sciences in Medicine 1989, 143-46.
- 11. Neurogenic claudication and root claudication treated with calcitonin: A double-blind trial**  
Porter RW, Miller CG. Spine 1989; 13(9):1061-4.
- 12. Ketorolac transfer into CSF**  
O' Sullivan GM, Rice ASC, Miller C, Lloyd J, Bullingham RES. European Journal Clinical Pharmacology 1989; 36S.

- 13. Broadband ultrasonic attenuation in the os calcis: relationship to bone mineral at other sites**  
McCloskey EV, Murray SA, Miller C, Charlesworth D, Tindale W, O'Doherty DP, Bickerstaff DR, Hamdy NAT, Kanis JA. *Clinical Science* 1990; 78:227–33.
- 14. Prediction of hip fracture in elderly women: A prospective study**  
Miller CG, Porter RW, Grainger D, Palmer SB. In *Osteoporosis 1990. The third international symposium on osteoporosis, Copenhagen, Denmark*. Edited by Christiansen C, Overgaard K.
- 15. Prediction of hip fracture in elderly women: A prospective study**  
Porter RW, Miller CG, Grainger D, Palmer SB. *British Medical Journal* 1990; 301:638–41.
- 16. Prediction of hip fracture in elderly women**  
Miller CG, Porter RW. *British Medical Journal* 1991; 302:50 (letter to the editor).
- 17. Bioavailability of two formulations of Naproxen enteric-coated 500 mg tablets in fasting and postprandial male volunteers following a single dose**  
Miller CG, Bullingham RES, Jonkman JHG. *Current Therapeutic Research* 1991; 49(5):740–9.
- 18. A double-blind study of the speed of onset of analgesia following the intramuscular administration of ketorolac tromethamine in comparison to intramuscular morphine and placebo**  
Rice ASC, Lloyd J, Miller CG, Bullingham RE, O'Sullivan GM. *Anesthesia* 1991; 46; 7:541–44.
- 19. Ultrasonic measurements in the calcaneus: a comparison of two commercial scanners**  
Ramalingam T, Herd RJM, Blake GM, Miller CG, Fogelman I. in *Current Research in Osteoporosis and Bone Mineral Measurement II: 1992 Ring EFJ Br. Inst Radiol* 1992.
- 20. Can ultrasonic measurements in the calcaneus predict osteopenia in the axial skeleton?**  
Herd RJM, Blake GM, Miller CG, Fogelman I. in *Current Research in Osteoporosis and Bone Mineral Measurement II: 1992. Ring EFJ Br. Inst Radiol* 1992.
- 21. Ultrasonic velocity measurements through the calcaneus: which velocity should be measured?**  
Miller CG, Herd RJM, Ramalingam T, Blake GM, Fogelman I. in *Current Research in Osteoporosis and Bone Mineral Measurement II: 1992 Ring EFJ Br. Inst Radiol* 1992.
- 22. Bone density measurements in clinical trials: the challenge of ensuring optimal data**  
Miller CG. Measurement of postmenopausal bone loss with a new contact ultrasound system. Herd RJM, Blake GM, Ramalingam T, Miller CG, Ryan PJ, Fogelman I. *Calcified Tissue International* 1993;53(3):153-7.
- 23. Should broadband ultrasonic attenuation be normalized for the width of the calcaneus?**  
Herd RJM, Blake GM, Miller CG, Fogelman I. in *Current Research in Osteoporosis and Bone Mineral Measurement III: 1994 Ring EFJ Br. Inst Radiol* 1994.
- 24. Optimal bone density measurements in clinical trials**  
Miller CG, in *Current Research in Osteoporosis and Bone Mineral Measurement III: 1994 Ring EFJ Br. Inst Radiol* 1994.
- 25. The ultrasonic assessment of osteopenia as defined by dual X-ray absorptiometry**  
Herd RJM, Blake GM, Miller CG, Parker JC, Fogelman I. *British Journal of Radiology* 1994; 67(799):631-5

**26. Entrance criteria for clinical trials with DEXA**

Miller CG, Barden HS. *Journal of Bone and Mineral Research* 1994; 9(Supplement 1):S209

**27. Cross-calibration of Dual Energy X-ray densitometers for a large, multi-centre genetic study of osteoporosis**

Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, Langdahl B, McLellan A, Pols H, Uitterlinden A, Riordan JO, Wass JAH, Ralston SH, Bennett ST. *Osteoporosis International* 2006;17(1):125-32.

**28. Vertebral morphometry using radiographs: comparison of manual and digitized images in expert software**

Miller CG, Ohlsson S, Borg J, Johnell O. *Osteoporosis International* 1996; 6(Supplement 1).

**29. New DEXA quality control methodology in clinical trials**

Miller CG, Lyons AR, Pye D, Fasano G, Horne S. *Journal of Bone and Mineral Research* 1997;12(Supplement 1):S5377.

**30. Dual energy x-ray absorptiometry (DXA) transmission methodology in clinical trials**

Miller CG, Lyons AR, Pye DW, Blaze M, Fasano GA, Horne S. *Drug Information Journal* 1998; 32-4

**31. A new hydroxyapatite spine phantom**

Nord RH, Bisek JP, Miller CG. *Osteoporosis International* 1997; 7:287.

**32. Heel ultrasound reference data for Caucasian women in the USA**

Rosen C, McClung M, Gallagher C, Baldwin D, Faulkner K, Trempe J, Miller C. *Journal of Clinical Densitometry*. 1998; 1(1):107.

**33. Instrument measurements in clinical trials – presenting the right image**

Miller CG. *European Pharmaceutical Contractor*. May 1998:84-9.

**34. Methodology for the clinical assessment of medical instrumentation: evaluating ultrasonometers**

Miller CG. *Journal of Clinical Densitometry*. 1998; 1(3):309-16.

**35. Cross calibration, precision, and patient dose measurements in preparation for clinical trials using dual energy X-ray absorptiometry of the lumbar spine**

Cawte SA, Pearson D, Green DJ, Masalanka WB, Miller CG, Rogers AT. *British Journal of Radiology*. 1999; 72(856):354-62.

**36. Precision of DXA measurements of the spine and total hip in adolescents**

Miller CG, Pak J, Caminis JN. *Journal of Bone and Mineral Research* 2001; 16(Supplement 1):S317.

**37. The use of medical imaging in clinical trials**

Miller CG. *SoCRA Source* November 2001; 30:26-8.

**38. Image Management in Clinical Trials**

Miller CG. *Business Briefing: Pharmatech* 2002

**39. Scanning data for clinical information**

Miller C, Noever K. *Good Clinical Practices Journal*. 2003. 10(9):21-4.

- 40. Reading Medical Images in Oncology Clinical Trials**  
Miller CG, Noever K. European Pharmaceutical Contractor. Summer 2004; 95-100.
- 41. Cross-calibration of Dual Energy X-ray densitometers for a large, multi-centre genetic study of osteoporosis**  
Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, Langdahl B, McLellan A, Pols H, Uitterlinden A, Riordan JO, Wass JAH, Ralston SH, Bennett ST. Osteoporosis International 2006;17(1):125-32.
- 42. Medical Imaging Core Laboratories. Applied Clinical Trials**  
Miller CG. 2nd Oct 2005  
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/author/authorDetail.jsp?id=22742>
- 43. Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site**  
Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, Carr A. Obesity 2007;15(6):1441-7.
- 44. Education Alternatives for imaging techniques in clinical trials**  
Miller CG, Wertz K. World Pharma Network. July 2007; 42-3.
- 45. Same Language, Different Message: The American Way from a British Perspective**  
Presentation at the Annual Meeting of the Institute of Clinical Research, April 2008 (Birmingham). Pub. CRFocus; June 2008; 19(6):75-6.
- 46. Medical imaging and electronic data capture in clinical trials: the future paradigm**  
Miller CG. International Pharmaceutical Industry (IPI) Spring 2009; 30-32.
- 47. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations**  
Fisher M, Feuerstein G, Howells et al. Stroke 2009; 40(6):2244-50.
- 48. Development of a clinical workflow tool to enhance the detection of vertebral fractures**  
Brett A, Miller CG, Hayes CW, Krasnow J, Ozanian T, Abrams K, Block J, van Kuijk C. Spine 2009;34(22):2437-43.
- 49. Quantitative Imaging Test Approval and Biomarker Qualification: Interrelated but Distinct Activities**  
Buckler, AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B. " " Radiology. 2011. 259(3): 875-884.
- 50. Mechanism of Action Study to Evaluate the Effect of Rosiglitazone on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus: Rationale, Study Design and Baseline Characteristics**  
Lorraine A. Fitzpatrick, John P. Bilezikianb, Margaret Wooddell, Gitanjali Paula, Nikheel S. Kolatgara, Antonio J. Ninoa, Colin G. Miller, Cesar E. Bogadof, Claude D. Arnaudg, Alexander R. Cobitza Journal of Drug Assessment 2012 Vol 1; 11-19.

- 51. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The ORACAL trial**  
Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS. *J Bone Miner Res.* 2012 Mar 21. 27(8):1821-1829
- 52. Metrics in Medical Imaging. Changing the picture.**  
HJ Yu, CG Miller, D Flitcraft. *Monitor.* (Peer reviewed), Aug 2012: 36 – 40.
- 53. A 2-Year Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Oral Selective Inos Inhibitor, Cindunistat, In Patients with Symptomatic Osteoarthritis of the Knee**  
MP. Hellio Le Graverand, R. Clemmer, P. Redifer, R. Brunell, C.W. Hayes, K. Brandt, S. Abramson, P. Manning, C. Miller, and E Vignon. *Ann Rheum Dis.* 2012 Nov 10. [Epub ahead of print] PubMed PMID: 23144445.
- 54. Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography**  
Hellio Le Graverand MP, Clemmer RS, Brunell RM, Hayes CW, Miller CG, Vignon E. *Semin Arthritis Rheum.* 2013 Jan 1. doi:pii: S0049-0172(12)00278-8. 10.1016/j.semarthrit.2012.11.006. [Epub ahead of print] PMID: 23290692.
- 55. Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials.** Navarro-Compán V, Landewé R, Ahmad HA, Miller CG, Xu D, Wolterbeek R, van der Heijde D. *Rheumatology (Oxford).* 2013 Jan 16. [Epub ahead of print] PMID: 23329683.
- 56. Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women with Type 2 Diabetes Mellitus**  
Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. *J Clin Endocrinol Metab.* April 2013, 98(4):1519–1528.
- 57. Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC)**  
Navarro-Compán V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewé R. *Ann Rheum Dis.* 2013 Apr 20. [Epub ahead of print] PMID: 23606704.
- 58. Atlas-Based Liver Segmentation and Hepatic Fat-Fraction Assessment for Clinical Trials**  
Yan, Z, Zhang, S., Tan, C., Belaroussi, B, Yu, H.J., Miller C., Metaxas, D. *Computerized Medical Imaging and Graphics*, 2014.
- 59. Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis**  
Eckstein F., Guermazi A., Gold G., Duryea J., Hellio Le Graverand MP., Wirth W., Miller CG. *Osteoarthritis and Cartilage.* 22(10):1516-32. doi: 10.1016/j.joca.2014.06.023. PMID: 25278061 [PubMed - in process] Free PMC Article. Oct 2014.
- 60. The current status of imaging in anti-NGF clinical trials**  
Miller, C.G., Guermazi, A., Roemer, F.W. *Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S3 - S7.* doi: 10.1016/j.joca.2014.09.002. Jan 2015.

- 61. Imaging Atlas for Eligibility and On-Study Safety of Potential Knee Adverse Events in anti-NGF studies (Part 1)**  
Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S22 - S42. doi: 10.1016/j.joca.2014.09.002. Jan 2015.
- 62. Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2)**  
Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S43 - S58. doi: 10.1016/j.joca.2014.09.002. Jan 2015.
- 63. Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3)**  
Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S59 - S68. doi: 10.1016/j.joca.2014.09.002. Jan 2015.
- 64. A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density**  
K B Hoover, C G Miller, N C Galante, C B Langman. Osteoporosis International. Doi: 10.1007/s00198-015-3158-2 May 2015
- 65. A DXA whole body composition cross-calibration experience: Evaluation with humans, spine, and whole Body phantoms**  
D. Krueger, J. Libber, J. Sanfilippo, H-J. Yu, B. Horvath, C.G. Miller, N. Binkley. Journal of Clinical Densitometry, doi: org/10.1016/j.jocd.2015.04.003 June 2015
- 66. OARSI Clinical Trials Recommendations: Hip imaging in clinical trials in osteoarthritis**  
G E Gold, F Cicuttini, M D Crema, F Eckstein, A Guermazi, R Kijowski, T M Link, E Maheu, J Martel-Pelletier, C G Miller, J-P Pelletier, C G Peterfy, H G Potter, F W Roemer, D J Hunter Osteoarthritis and Cartilage. DOI:10.1016/j.joca.2015.03.004 May 2015; 23(5):716-731
- 67. OARSI Clinical Trials Recommendations: Knee imaging in clinical trials in osteoarthritis**  
D J Hunter, RD Altman, F Cicuttini, M D Crema, J Duryea, F Eckstein, A Guermazi, R. Kijowski, TM Link, , J Martel-Pelletier, C G Miller, TJ Mosher, R E Ochoa-Albíztegui, J-P Pelletier, C Peterfy, J-P Raynauld, F Roemer, SM Totterman, G E Gold. Osteoarthritis and Cartilage. DOI:10.1016/j.joca.2015.03.004 • May 2015; 23(5):698-715
- 68. OARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritis**  
D J Hunter, N Arden, F Cicuttini, M D Crema, B Dardzinski, J Duryea, A Guermazi, I K Haugen, M Kloppenburg, E Maheu, C G Miller, J Martel-Pelletier, R E Ochoa-Albíztegui, J-P Pelletier, C Peterfy, F Roemer, G E Gold. Osteoarthritis and Cartilage. DOI:10.1016/j.joca.2015.03.003 May 2015; 23(5):732-746

**69. A DXA Whole Body Composition Cross-Calibration Experience: Evaluation With Humans, Spine, and Whole Body Phantoms**

Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S22 - S42. doi: 10.1016/j.joca.2014.09.002. Jan 2015.

**70. Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint**

Colin G Miller, Cesar C Bogado, Antonio J Nino, Allison R Northcutt, Hui Jing Yu, E Michael Lewicki, G Paul, Alexander R Cobitz, Margaret J Woodall, John P Belizikian, Lorraine A Fitzpatrick. J Clinical Densitometry 2016. <http://dx.doi.org/10.1016/j.jocd.2016.02.003>

**71. Development of an imaging mitigation strategy for patient enrolment in the Tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment**

Frank W. Roemer, Colin G. Miller, Christine R. West, Mark T. Brown, Sarah P. Sherlock, Andrew J. Koppel, Luis Diaz, Nicholas Galante, Michel D. Crema, Ali Guermazi. Journal: Seminars in Arthritis and Rheumatism. May 2017. <http://dx.doi.org/10.1016/j.semarthrit.2017.05.008>



**1. Gravity induced list**

Porter RW, Miller CG. Presented at the International Society for Studies in the Lumbar Spine 1984. Also presented at the Society of Back Pain Research.

**2. Neurogenic claudication and root claudication: A trial comparing calcitonin and placebo.**

Porter RW, Miller CG. Presented at the International Society for Studies in the Lumbar Spine.

**3. The prediction of fracture of the proximal femur by broadband ultrasonic attenuation**  
Miller CG, Porter RW, Palmer SB. Presented at the Sixth International Workshop on Bone and Soft Tissue Densitometry

**4. The prediction of fracture of the proximal femur by broadband ultrasonic attenuation**  
Miller CG, Porter RW, British Orthopaedic Research Society, October 1987.

**5. Osteoporosis and its relationship to home safety.**

Miller CG. Invited speaker to the Southern Home Safety Council of Great Britain, September 1989.

**6. A novel measurement of the onset time of analgesic following an intramuscular injection of ketorolac, morphine and placebo**

Rice ASC, O'Sullivan G, Bullingham R, Lloyd J, Miller CG. Presented at the VI World Congress of Pain, Australia, 1990.

**7. The ultrasonic assessment of bone - A review.**

Invited Plenary Lecture at the Danish Bone and Tooth Society meeting, Denmark, 1991.

**8. The application of ultrasound in clinical trials**

Invited lecture at the German Symposium on The Ultrasonic Assessment of Bone, March 1992.

**9. The pharmaceutical industry perspective on bone mineral measurement**

Invited speaker at the Workshop on Bone Densitometry for Radiographers, Manchester, 1992.

**10. The pharmaceutical industry perspective on bone mineral measurement.**

Invited speaker at the Workshop on Bone Densitometry for Members of the Association of Clinical Research in the Pharmaceutical Industry, May 1992.

**11. Ultrasonic velocity measurements through the calcaneus: which velocity should be measured?**

Miller CG, Herd RJM, Ramalingam T, Blake GM, Fogelman. Presented at The Second International Symposium on the Ultrasonic Assessment of Bone, 1992.

**12. Can ultrasound measurements in the calcaneus predict osteopenia in the axial skeleton?**

Herd RJM, Blake GM, Miller CG, Parker JC, Fogelman I. Calcified Tissue International. 1993; 52:170 (Abstract 66).

**13. Calcaneal ultrasound velocity measurements: which parameter should be measured?**

Miller CG, Herd RJM, Ramalingam T, Blake GM, Fogelman I. Calcified Tissue International. 1993; 52: 170 (Abstract 67).



**14. A comparison of three commercial bone ultrasound scanners.**

Ramalingam T, Herd RJM, Lees B, Blake GM, Stevenson JC, Miller CG, Fogelman I. *Calcified Tissue International*. 1993; 52:170 (Abstract 68).

**15. The pharmaceutical industry perspective on bone mineral measurement.**

Invited speaker at the Workshop on Bone Densitometry for Radiographers, Manchester, March 1993.

**16. The use of bone densitometry in clinical trials.**

Invited speaker at the Workshop on Bone Densitometry in Clinical Research by the Association of Clinical Research in the Pharmaceutical Industry, May 1993.

**17. The use of bone densitometry in clinical trials.**

Invited paper at the Hologic Users Meeting UK, November 1993.

**18. The use of bone densitometry in clinical trials**

Invited paper at the Lunar Users Meeting UK, February 1994.

**19. The ultrasonic assessment of bone: A review**

Invited paper at the Lunar Users Meeting UK, February 1994.

**20. Ultrasonic velocity measurements through the calcareous: The Relationship Between Bone and Heel Velocities**

Blake G, Herd R, Fogelman I, Miller C. Symposium on the Ultrasonic Assessment of Bone, 1994.

**21. Bone density measurements in clinical trial: The challenge of ensuring optimal instrument quality control (poster)**

Miller, CG. Associates of Clinical Pharmacology, April 1995.

**22. Dual energy x-ray absorptiometry: Current standards - future developments**

Invited speaker at the Cambridge Healthtec Institutes Bi-Annual Conference on the Treatment of Osteoporosis, Philadelphia, Pennsylvania, USA, May 1995.

**23. Instrument quality control of DXA in clinical trials**

Miller, CG. 11th International Bone Densitometry Workshop, Glenden Beach, Oregon, USA, September 1995.

**24. Vertebral morphometry using radiographs: Comparison of manual and digitized images in EXPERTTM software**

Miller CG, Ohlsson S, Borg J, Ohnell J. World Congress on Osteoporosis, May 1996.

**25. New DEXA quality control methodology in clinical trials (poster)**

Miller CG, Lyons AR, Pye D, Fasano G, Horne S. Third Biennial conference on the treatment of osteoporosis by Cambridge Healthtech Institute, Philadelphia, Pennsylvania, USA, October 1996.

**26. DEXA technology: update in the diagnosis of osteoporosis**

Invited paper at the Third Biennial conference on the treatment of osteoporosis by Cambridge Healthtech Institute, Philadelphia, Pennsylvania, USA, October 1996.

**27. Clinical ultrasonometry today and tomorrow**

1st International Workshop on Bone Ultrasonometry, Edinburgh, Scotland, May 1997.

**28. A new hydroxyapatite spine phantom**

Nord RH, Bisek JP, Miller CG. 12th International Workshop on Bone Density, Creiff, Scotland, May 1997.

**29. A DXA body composition cross calibration phantom**

Formica C, Nieves J, Dixon J, Munn L, Lindsay R, Miller CG. 12th International Workshop on Bone Densitometry, Crieff, Scotland, May 1997.

**30. Requirements for clinical instrumentation**

The 2nd International Workshop on Bone Ultrasonometry, Heidelberg, Germany, April 1998.

**31. Quality assurance of bone mineral density around hip prosthesis**

Miller CG, Lyons A, Pye D, Vincent R, Blaize M, Fasano G, Carr A. Bath Osteoporosis and Bone Mineral Measurement, Bath U.K., June 1998.

**32. DEXA measurements for hip arthroplasty: ensuring optimal data**

Invited speaker Satellite Orthopedic meeting; Bath Osteoporosis and Bone Mineral Measurement, June 1998.

**33. Instrument quality control in body composition studies using in-scan phantoms**

Carr AP, Miller CG, Nord RH, Binkley N, Dixon CJ, Munn L. 13th International Bone Densitometry Workshop, Delavan, Wisconsin, October 1998.

**34. Long-term evaluation of the European spine phantom in multi-center clinical trials**

Behnke SB, Miller CG. 13th International Bone Densitometry Workshop, Delavan, Wisconsin, October 1998.

**35. Evaluation of a new calcium hydroxyapatite phantom for DEXA cross calibration and IQC**

Peterson MK, Miller CG, Carr AP. 13th International Bone Densitometry Workshop, Delavan Wisconsin, October 1998.

**36. Alendronate prevents periprosthetic bone loss**

Lyons AR, Freedholm DA, Yates AJ, Owen JE, Pye D, Wallace WA, Miller CG, Fasano G, Malbecq W. American College of Rheumatology Annual Meeting, San Diego, California, November 1998.

**37. Optimum measurements for Clinical trials in osteoporosis**

Miller CG. Invited speaker at Symposium; Imaging in Clinical Trials. Drug Information Association, Philadelphia, Pennsylvania, USA, May 1999.

**38. Imaging in clinical trials**

Miller CG. Chairman and speaker at workshop; Imaging in Clinical Trials; Ensuring the Right Image. Drug Information Association Annual Meeting, Baltimore, Maryland, June 1999.

**39. Bone Densitometry in Clinical Trials: Ensuring Optimal Data**

Miller CG Invited speaker at Symposium; Imaging in Clinical Trials. Barnett International, Washington, September 1999.

**40. Methodologies for the evaluation of osteoporosis: An overview**

Miller CG. Invited Speaker and workshop leader at the SMi Symposium; Novel and emerging therapies for the treatment of osteoporosis. London, June 2000.

**41. DXA/DEXA in osteoporosis**

Miller CG Invited speaker at Second Annual Symposium; Imaging in Clinical Trials. Drug Information Association, Washington, May 2000.

**42. The use of imaging technologies in clinical trials**

Miller CG. Invited speaker at the 9th Annual Conference for the Society of Clinical Research Associates, Washington, September 2000.

**43. Imaging Technologies in Ischaemic Drug Discovery and Development**

Speaker and workshop leader. SMi Conference and Workshop, London, January 2001.

**44. Imaging in osteoporosis**

Miller CG. Invited speaker at Third Annual Symposium; Medical Imaging in Clinical Trials. Drug Information Association, Washington, March 2001.

**45. Applications of Imaging to Clinical Drug Development**

Invited Speaker at SMi Conference on Medical Imaging: Benchmarking for Clinical Trial Efficiency, London, June 2001.

**46. Medical Imaging in Clinical Trials: The Current Picture**

Workshop leader and presenter on The Issues of Site Training and Certification at SMi Workshop, London, June 2001.

**47. The Role of Imaging Bio-Markers in the Evaluation of Inflammatory Disease**

Miller CG. Invited speaker and Session Chair at The International Inflammation Research Meeting, Vancouver 2003. Sessions; Biomarkers and Imaging.

**48. Choice of Cross-Calibration Phantom for DXA of the Lumbar Spine and Total Hip**

Jackson, SA., Miller, CG. J. Bone Min. Res. 18, Suppl. 2. S.314, 2003.

**49. Imaging Endpoints: Employing Blinded Read Methodologies**

Miller CG. Invited Speaker at Medical imaging for Oncology Clinical Trials by CBI, Philadelphia, Pennsylvania, USA, October 2004.

**50. Imaging in Osteoporosis Clinical Trials**

Invited Presentation to the FDA, Imaging Group, headed by Dr. George Mills. April 2005.

**51. Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site**

Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, Carr A for The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the Body Composition Substudy of Strategies for Management of Anti-Retroviral Therapy (SMART-CPCRA 065C). Obesity 2nd October 2006. ID 06-0357-orig.

**52. The Difference in Imaging between Routine Clinical and Clinical Trials**

Invited Presentation at the High Country Society of Nuclear Medicine Meeting in Vail, March 2007.

- 53. Automated assessment of vertebral shape on lateral radiographs by statistical shape modeling (oral presentations)**  
Brett AD, Krasnow J, Miller C, van Kuijk C, Abrams K, Hayes C. Radiological Society of North America (RSNA) Scientific Meeting, 2007:407.
- 54. Automated assessment of vertebral shape on lateral radiographs by statistical shape modeling**  
Brett AD, Krasnow J, Miller C, Haslam J, Ozanian T, van Kuijk C, Abrahams K, Cope C, Beke M, Hayes C. J. Bone and Mineral Research 2007; 22(Supplement 1):S419.
- 55. Reproducibility of radiographic anatomical axis measurement of the knee using a software workflow tool**  
Miller CG, Brett A, Yogmas C, Dawson E, Lacey A. Osteoarthritis and Cartilage 2007; 5(Supplement C):S194.
- 56. Measurement of the Knee using a Software Workflow Tool**  
C Miller, A Brett, C Yogmas, E Dawson, A Lacey. Reproducibility of Radiographic Anatomical Axis. In Osteoarthritis Cartilage, 15 SuppC (Proceedings of OARSI), 347, Florida, December 2007.
- 57. Same Language, Different Message: The American Way from a British Perspective**  
Presentation at the Annual Meeting of the Institute of Clinical Research, April 2008 (Birmingham). Pub. CRFocus; June 2008, Vol 19, No 6 p75-76.
- 58. Automatic classification of vertebral shape based on statistical shape modeling**  
Haslam J, Hayes C, Ozanian T, Miller C, Krasnow K, Cope R, Brett A. NOF Meeting 2009.
- 59. Osteoporosis Clinical Trials: Go/No Go Decisions**  
Invited presentation at The Center for Business Intelligence February 2009, 6th Annual Imaging in Clinical Trials, Tysons Corner, Virginia.
- 60. Effects of Rosiglitazone on Bone: Assessing QCT Parameters in a Mechanistic Study of Postmenopausal Women with Type 2 Diabetes Mellitus (poster)**  
Bilezikian JP, Kravitz BG, Lewiecki EM, Miller CG, Northcutt AR, Paul G, Cobitz A, Nino AJ, Fitzpatrick LA. American Society of Bone and Mineral Research (ASBMR), October 2010.
- 61. Reproducibility of a Vertebral Deformity Tool (VDT) using an Active Shape Modeling Workflow Tool (Plenary Poster)**  
CG Miller, PhD, A Brett\*, E Bogner+, M Tan\*\*, R Cope, MB Jenkins\*\*, J Haslam\*, P Steiger\*, CW Hayes†, American Society of Bone and Mineral Research (ASBMR), September 2011. **Also invited to present the poster at the IOF-ECCEO meeting in Bordeaux, March 2012.**
- 62. Effects of Rosiglitazone on Bone: A Mechanistic Study of Postmenopausal Women with Type 2 Diabetes Mellitus (oral presentation)**  
Fitzpatrick LA, Bilezikian JP, Kravitz BG, Lewiecki EM, Miller CG, Northcutt AR, Paul G, Cobitz A, Nino AJ., American Society of Bone and Mineral Research IOF-ECCEO meeting, Bordeaux, March 2012.

- 63. Prediction of rate of adjudication of radiological progression in rheumatoid arthritis (RA) randomized controlled trials (RCTS) in early and established disease**  
V. Navarro-Compán, R. Landewé, H. Ahmad, C. Miller, D. van der Heijde. EULAR May 2012, Berlin
- 64. Calculation of the smallest detectable change (SDC) of radiographic progression in clinical trials with multiple time points: The mean SDC is a valid approximation of the overall SDC**  
V. Navarro-Compán, D. van der Heijde, H. Ahmad, C. Miller, R. Landewé. EULAR 2012 May, Berlin Practical.
- 65. X-Ray Acquisition Challenges in Clinical Trials: Challenges and Solutions Posed By the Synflexer™**  
McCarrie R and Miller CG. Poster presentation at the Osteoarthritis Imaging Conference, Hilton Head, July 2012.
- 66. A 2-Year Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Oral Selective Inos Inhibitor, Cindunistat, In Patients with Symptomatic Osteoarthritis of the Knee. (Oral presentation at the Osteoarthritis Imaging Conference, Hilton Head)**  
MP. Hellio Le Graverand, R. Clemmer, P. Redifer, R. Brunell, C.W. Hayes, K. Brandt, S. Abramson, P. Manning, C. Miller, and E Vignon. July 2012.
- 67. Considerations When Designing A DMOAD Clinical Trial Using Radiography**  
MP. Hellio Le Graverand, R. Clemmer, R. Brunell, C.W. Hayes, C. Miller, and E Vignon. Oral presentation at the Osteoarthritis Imaging Conference, Hilton Head, July 2012.
- 68. Use of Imaging Biomarkers in Clinical Studies/Trials**  
Invited presentation at the Osteoarthritis Imaging Conference, Hilton Head, July 2012.
- 69. How to optimize x-ray acquisition in OA clinical trials**  
Invited presentation at the Osteoarthritis Imaging Conference, Djerba, Tunisia, July 2013.
- 70. Safety end points on skeletal integrity in Metabolic Diseases: Learning's from Rosiglitazone and Canagliflozin**  
Invited presentation at the Phacilitate Metabolic Opinion Leaders Forum, Boston, October 2013.
- 71. A DXA body composition cross-calibration experience using phantoms and humans (Oral presentation at ISCD meeting in Orlando)**  
J.Libber, D. Krueger, J. Sanfilippo, HJ. Yu, C. Miller, N. Binkley. Osteo Int (2014) 25 (suppl 1): S13.
- 72. Automatic Liver Segmentation and Hepatic Fat Fraction Assessment in MRI. ICPR, 2014**  
Zhennan Yan, Shaoting Zhang, Chaowei Tan, Yan Zhou, Boubakeur Belaroussi, Hui Jing Yu, Colin Miller, Dimitris Metaxas.
- 73. A Robust and Automatic Framework for Assessment of the Muscle/Fat Fraction in Thigh. ICPR, 2014**  
Chaowei Tan, Zhennan Yan, Shaoting Zhang, Boubakeur Belaroussi, Hui Jing Yu, Colin Miller, Dimitris Metaxas.
- 74. Automatic Liver Segmentation and Hepatic Fat Fraction Assessment in MRI. ICPR, 2014**  
Zhennan Yan, Chaowei Tan, Shaoting Zhang, Yan Zhou, Boubakeur Belaroussi, Hui Jing Yu, Colin Miller, Dimitris Metaxas.

**75. A Robust and Automatic Framework for Assessment of the Muscle/Fat Fraction in Thigh. ICPR, 2014**

Chaowei Tan, Zhennan Yan, Shaoting Zhang, Boubakeur Belaroussi, Hui Jing Yu, Colin Miller, Dimitris Metaxas.

**76. Imaging findings in anti-nerve growth factor (a-NGF) studies: Relevance for eligibility and safety**

Roemer F.W., Miller C., Hoover K.B., Hayes C.W., Guermazi A. 2014

**77. International Workshop on Osteoarthritis Imaging.**

July 2014, Iceland.

**78. Differences between radiologic assessment in osteoarthritis efficacy studies and nerve growth factor inhibitor programs: Relevance of radiographic and MRI**

Guermazi A., Hellio-Le Graverand M.-P., Miller C., Roemer F.W. 2014. International Workshop on Osteoarthritis Imaging. July 2014, Iceland.

**79. Reproducibility of a semi-automatic knee joint analysis tool**

Yu H.J., Zhang Y., Morges S., Dawson E., Galante N., Belaroussi B., Hoover K.B., Miller C.G. 2014. International Workshop on Osteoarthritis Imaging. July 2014, Iceland.

**80. A semi-automated software for minimal joint space width detection in hip radiographs**

Yu H.J., Zhang Y., Morges S., Dawson E., Galante N., Belaroussi B., Hoover K.B., Miller C.G. 2014. International Workshop on Osteoarthritis Imaging. July 2014, Iceland.

**81. Tissue Quantification thigh MRI in osteoarthritis**

A double-blind, randomized, Phase III, multicenter study in 300 pediatric subjects receiving isotretinoin therapy demonstrate no effect on pediatric bone mineral density Kevin Hoover, Colin Miller, Craig Langman, Rick Gilbert, Jason Gross. Yu H.J., Tan C., Yan Z., Belaroussi B., Zhang Y., Metaxas D., Carrino J.A., Miller C.G. 2014. International Workshop on Osteoarthritis Imaging. July 2014, Iceland.

**82. Age-related changes of thigh muscle fat infiltration in subjects of the OAI MRI cohort without non-radiographic osteoarthritis**

Hui Jing Yu, PhD1, Chaowei Tan2, Zhennan Yan2, Colin G. Miller, PhD1, Thomas Fuerst, PhD1, Klaus Engelke, PhD1, Dimitri Metaxas, PhD2 (1) BioClinica, Inc. USA and Germany (2) Rutgers University, USA. International Conference on frailty and sarcopenia Research. Boston, April 2015.

**83. Study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in patients with GEP-NETs**

Virgolini I, Brouwers A, Haug A, Gronbaek H, Kjaer A, Novac D, Ang A, Miller C, Kaufmann J, Czernin J. Presented at the 15th Annual ENETS Conference, Barcelona, Spain, March 7-9, 2018 GEP-NETS. Virgolini I, Brouwers A, Haug A, Gronbaek H, Kjaer A, Novac D, Ang A, Miller C, Kaufmann J, Czernin J. Presented at the 15th Annual ENETS Conference, Barcelona, Spain, March 7-9, 2018.

**84. A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with GEP-NETs in a phase II clinical trial**

Miller C, Virgolini I, Kjaer A, Henning G, Terve P, Shamsi K, McEwan S, Bahri S, Presented at SNMMI, May 2020.

**85. A phase II clinical trial to evaluate the optimal activity range and peptide mass dose range of  $^{68}\text{Ga}$ -satoreotide trizoxetan as a PET imaging agent in patients with GEP-NETSs**

Virgolini I, Bahri S, Kjaer A, Henning G, Czernin J, Powell C, Miller C, Rohban T, Presented at SNMMI, May 2020.

**86. A novel read methodology to evaluate the optimal dose of  $^{68}\text{Ga}$ -satoreotide trizoxetan as a PET imaging agent in patients with GEP-NETSs in a Phase II Clinical Trial**

Miller C, Virgolini I, Kjaer A, Gronbaek H, Terve P, Shamsi K, McEwan S, Bahri S, Presented at SNMMI, July 2020.

**87. Optimal Dose of  $^{68}\text{Ga}$ -satoreotide trizoxetan as a PET imaging agent in patients with Gastroenteropancreatic Neuroendocrine Tumours: Qualitative Analysis of PET Images**

Miller C, Virgolini I, Kjaer A, Gronbaek H, J Czernin, E. von Guggenberg, S. McEwan Presented at SNMMI, May 2020.